BusinessMelinta Therapeutics Provides for Distribution of Delafloxacin to 19 Countries via Extended Agreement with Eurofarma LaboratóriosBy Nasdaq OMXSep 26, 2017, 12:01 PM UTC
BusinessMelinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other InfectionsBy Nasdaq OMXSep 25, 2017, 12:01 PM UTC
BusinessMelinta Therapeutics’ Phase 3 trials of Baxdela Document Challenges in Antibiotic Selection in Patients Treated for ABSSSIBy Nasdaq OMXMay 2, 2017, 1:39 PM UTC
BusinessMelinta Therapeutics Updates Pyrrolocytosine and Enhanced Macrolide Programs at ECCMID Showcasing Company’s Structure-Based Drug DesignBy Nasdaq OMXApr 21, 2017, 1:56 PM UTC
BusinessMelinta Therapeutics Presentations at ECCMID Show Potential of Baxdela in Obese and other Challenging Patient TypesBy Nasdaq OMXApr 21, 2017, 1:37 PM UTC
BusinessMelinta Therapeutics Highlighting Activity of Baxdela as well as Progress on Macrolide and Pyrrolocytosine Candidates at ECCMID 2017By Nasdaq OMXApr 19, 2017, 6:43 PM UTC
